U-50488

U-50488
Tanımlayıcılar
CAS Numarası	67198-13-4;
PubChem CID	3036289;
CompTox Bilgi Paneli (EPA)	DTXSID60953023 ;
Kimyasal ve fiziksel veriler
Formül	C19H26Cl2N2O

U-50488, oldukça seçici bir κ-opioid agonisti olarak işlev gören, ancak herhangi bir μ-opioid antagonist etkisi olmayan bir ilaçtır.^[1] Analjezik, idrar söktürücü ve öksürük kesici etkileri vardır^[2] ve antikolinerjik ilaçlar tarafından üretilen hafıza bozukluğunu tersine çevirir.^[3] U-50488, icat edilen ilk seçici kappa agonistlerinden biridir ve türevleri üzerine yapılan araştırmalar, ilgili bileşikler ailesinin geliştirilmesine yol açmıştır.^[4]^[5] Bu bileşik hiçbir zaman FDA onayı almamıştır.^[6]

Kaynakça

^ "U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 6 (4–6): 467-70. 1982. doi:10.1016/S0278-5846(82)80130-9. PMID 6298890.
^ "Role of opioidergic and serotonergic mechanisms in cough and antitussives". Pulmonary Pharmacology. 9 (5–6): 349-56. 1996. doi:10.1006/pulp.1996.0046. PMID 9232674.
^ "Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models". Methods and Findings in Experimental and Clinical Pharmacology. 20 (7): 595-9. September 1998. doi:10.1358/mf.1998.20.7.485724. PMID 9819804.
^ "U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 52: 167-95. 1999. doi:10.1007/978-3-0348-8730-4_4. PMID 10396128.
^ "U-50,488 and the kappa receptor. Part II: 1991-1998". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 53: 1-51. 1999. PMID 10616295.
^ "Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488". Cureus. 9 (12): e1914. December 2017. doi:10.7759/cureus.1914. PMC 5800751 . PMID 29441248.

[1] "U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 6 (4–6): 467-70. 1982. doi:10.1016/S0278-5846(82)80130-9. PMID 6298890.

[2] "Role of opioidergic and serotonergic mechanisms in cough and antitussives". Pulmonary Pharmacology. 9 (5–6): 349-56. 1996. doi:10.1006/pulp.1996.0046. PMID 9232674.

[3] "Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models". Methods and Findings in Experimental and Clinical Pharmacology. 20 (7): 595-9. September 1998. doi:10.1358/mf.1998.20.7.485724. PMID 9819804.

[4] "U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 52: 167-95. 1999. doi:10.1007/978-3-0348-8730-4_4. PMID 10396128.

[5] "U-50,488 and the kappa receptor. Part II: 1991-1998". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 53: 1-51. 1999. PMID 10616295.

[6] "Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488". Cureus. 9 (12): e1914. December 2017. doi:10.7759/cureus.1914. PMC 5800751 . PMID 29441248.

[1]

[2]

[3]

[4]

[5]

[6]